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HIV-1 Tat-shortened neurite outgrowth
through regulation of microRNA-132 and
its target gene expression
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Abstract
Background: Synaptodendritic damage is a pathological hallmark of HIV-associated neurocognitive disorders, and
HIV-1 Tat protein is known to cause such injury in the central nervous system. In this study, we aimed to determine
the molecular mechanisms of Tat-induced neurite shortening, specifically the roles of miR-132, an important
regulator of neurite morphogenesis in this process.
Methods: The relationship between Tat expression and miR-132 expression was first determined using reverse
transcription quantitative PCR (qRT-PCR) in Tat-transfected astrocytes and neurons, astrocytes from Tat-transgenic
mice, and HIV-infected astrocytes. qRT-PCR and Western blotting were performed to determine Tat effects on
expression of miR-132 target genes methyl CpG-binding protein 2, Rho GTPase activator p250GAP, and brain-derived
neurotrophic factor. Exosomes were isolated from Tat-expressing astrocytes, and exosomal microRNA (miRNA) uptake
into neurons was studied using miRNA labeling and flow cytometry. The lactate dehydrogenase release was used to
determine the cytotoxicity, while immunostaining was used to determine neurite lengths and synapse formation. Tat
basic domain deletion mutant and miR-132 mimic and inhibitor were used to determine the specificity of the
relationship between Tat and miR-132 and its effects on astrocytes and neurons and the underlying mechanisms of
Tat-induced miR-132 expression.
Results: Tat significantly induced miR-132 expression, ensuing down-regulation of miR-132 target genes in astrocytes
and neurons. miR-132 induction was associated with phosphorylation of cAMP response element-binding protein and
required the basic domain of Tat. miRNA-132 induction had no effects on astrocyte activation or survival but was
involved in the direct neurotoxicity of Tat. miR-132 was present in astrocyte-derived exosomes and was taken up by
neurons, causing neurite shortening.
Conclusions: Tat-induced miR-132 expression contributes to both direct and astrocyte-mediated Tat neurotoxicity and
supports the important roles of miR-132 in controlling neurite outgrowth.
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Background
Human immunodeficiency virus type 1 (HIV-1) enters
the central nervous system (CNS) during the acute
phase of the infection and results in the production of
viral proteins and activation of microglia/macrophages
and eventually injury to neurons [1, 2]. Before the intro-
duction of combination antiretroviral therapy (cART),
HIV-1 infection of the CNS resulted in HIV-1-associated
dementia (HAD) in up to 15 % of the infected individ-
uals [3]. The success of cART in the suppression of ac-
tive HIV replication dramatically reduced the severity of
neurocognitive impairments as evident by the decrease
in HAD cases to 2 % [4]. Meanwhile, a less severe form
of HIV-associated neurocognitive disorders (HAND),
termed minor cognitive and motor disorder (MCMD), is
being detected in more than 50 % of HIV-infected indi-
viduals [5]. Synaptodendritic injury is a positive correlate
of MCMD and has become a reliable indicator of
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cognitive impairment of HIV-infected individuals as op-
posed to neuronal loss [6–9]. In addition, synaptic loss
has been described in the context of neuroinflammation
associated with HIV-1 invasion of the CNS [10, 11].
However, the exact underlying molecular mechanisms of
HIV-associated synaptodendritic injury and synaptic loss
remain largely unknown.
MicroRNA (miRNA) are master translation regulators
which generally initiate degradation of messenger RNA
(mRNA) and translational repression [12]; they are often
dysregulated in diseases [13–15]. Viral infections in
particular have been shown to disrupt cellular miRNA
profiles and thus modulate viral replication or the tran-
scriptional machinery of the host [16]. In HIV-1 infec-
tion, down-regulation of host miRNA has been linked to
anti-viral immunity and replication [17, 18]. miRNA are
extensively expressed in the CNS and have broadly been
studied in differentiation, dendrite growth, and synaptic
function of neurons [19–21]. microRNA profiling of the
brain tissues of cognitively impaired HIV patients have
revealed differential expression signatures of miRNA in
the regulation of dendrite formation and branching
[22–25]. Among those is miR-132. miR-132 is one of
the best defined miRNA in the CNS, and its roles in
dendrite morphology and synapse function have been
characterized [26, 27], through two extensively studied
miR-132 target genes in dendrites: Rho GTPase activa-
tor p250GAP [28] and methyl CpG-binding protein 2
(MecP2) [29, 30]. Brain-derived neurotrophic factor
(BDNF) is directly and positively regulated at the tran-
scription level by MecP2 and thus can be considered an
indirect target of miR-132 [31, 32]. Notably, dysregula-
tion of miR-132 has been reported in a number of psy-
chiatric, neurodevelopmental, and neurodegenerative
diseases [33–35]. Outside the CNS, miR-132 has been
shown to be highly up-regulated in HIV-infected CD4+
T cells [36]. These findings raise the possibility that
miR-132 plays important roles in HIV infection and
pathogenesis in the CNS.
Tat is indispensable for HIV-1 transcription and repli-
cation (see review [37]). Tat is also important for HAND,
as it is a potent neurotoxin and causes direct acute dam-
age to neurons in both in vitro and in vivo [38–41]. Des-
pite the restricted nature, HIV-1 infection of astrocytes
leads to abundant expression of HIV-1 early gene prod-
ucts Tat, Nef, and Rev proteins [42–45]. Tat possesses a
unique property, i.e., release from one cell and uptake by
the other cell [46, 47]. Consistent with these findings, Tat
is present in the CNS of HIV-infected individuals [48, 49]
and expressed in and secreted by HIV-1 latently infected
astrocytes [50–52]. In addition, Tat adversely affects
neuron survival at more physiologically relevant concen-
trations through cytokine expression, excitatory proper-
ties, intracellular signaling, autophagy, and lysoendosomal
function in the neurons [53–56]. Importantly, astrocytes
have been shown to potentiate Tat neurotoxicity [40, 50,
57, 58]. HIV-1 Tat protein alone is capable of reducing
synaptic protein levels and dendritic arbor [59–64]. Of
particular note is that Tat expression in astrocytes alone is
capable of inducing pathological changes such as loss of
axons and dendrites and neurobehavioral changes such as
impaired motor and cognitive functions in the CNS rem-
iniscent of HAND [57, 65, 66]. HIV-1 Tat itself has been
shown to inhibit anti-viral miRNA expression in periph-
eral blood mononuclear cells [67]. In the context of HIV-1
infection of the CNS, Tat has been reported to alter
miRNA expression in neurons and affect neuronal func-
tion [68, 69]. In this study, we used a combined molecular,
cellular, and genetic approach and determined the direct
relationship between Tat and miR-132 expression and its
possible contribution to Tat-induced changes in neurite
outgrowth and synapse formation.
Methods
Cells and cell cultures
Human kidney epithelial cells 293T, human astrocytoma
cells U373.MG and U138.MG, and human neuroblast-
oma cells SH-SY5Y were purchased from American
Type Culture Collection (ATCC, Manassas, VA) and
maintained in Dulbecco’s modified Eagle’s medium
(DMEM), supplemented with 10 % fetal bovine serum
(FBS), 50 U/ml penicillin, and 50 μg/ml streptomycin in
a 37 °C, 5 % CO2 incubator. SH-SY5Y were differenti-
ated by sequential treatment with retinoic acid and
BDNF as described previously [70] and maintained in
50:50 F-12 HAM/DMEM and 10 % FBS without antibi-
otics. Primary human astrocytes were prepared as de-
scribed previously [49]. Primary astrocytes were cultured
in an F12-K medium (Cellgro, Manassas, VA) containing
10 % FBS, 50 U/ml penicillin, and 50 μg/ml strepto-
mycin in a 37 °C, 5 % CO2 incubator and passaged every
3–4 days. Primary mouse astrocytes were isolated from
18.5-day-old embryonic brain tissue of the doxycycline-
inducible astrocyte-specific Tat-transgenic mice (iTat) or
C57B/L6 wild-type mice (WT) as described previously
[40]. Primary mouse cortex neurons were isolated from
day-17 embryonic C57BL/6 mice, purchased from
GIBCO (Langley, OK), and maintained in a Neurobasal
medium (GIBCO) supplemented with 1 % B27, 50 U/ml
penicillin, and 50 μg/ml streptomycin in a 37 °C, 5 %
CO2 incubator.
Plasmids, miRNA, and transfections
cDNA3 plasmid was purchased from Clontech (Mountain
View, CA). Tat.Myc and Tat.His plasmids were previously
described [71]. Mutant Tat plasmid with deletion of the
basic domain region, aa 49-57 (ΔBD), was constructed
using the QuikChange II XL Site-Directed Mutagenesis Kit
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(Stratagene, La Jolla, CA) with Tat.His as the template and
primers 5′-GGC ATC TCC TAT GGC CCT CCT CAA
GGA TCC-3′ and 5′-GGA TCC TTG AGG AGG GCC
ATA GGA GAT GCC-3′. All recombinant plasmids were
verified by sequencing. Synthetic miR-132 mimic (Mission
microRNA hsa-miR-132, Cat. HMI0190, mature sequence
ACCGUGGCUUUCGAUUGUUACU) and miR-132
inhibitor (Mission microRNA, hsa-miR-132, Cat.
HSTUD0191, mature sequence UAACAGUCUACAGCC
AUGGUCG) duplexes along with negative control miRNA
(Mission microRNA Negative Control 1, Cat. HMC003,
mature sequence CGGUACGAUCGCGGCGGGAUAUC)
were purchased from Sigma (Sigma-Aldrich, St. Louis,
Mo). miR-132 labeling was performed using a Mirus Label
IT miRNA Cy3 Kit (Madison, WI) according to the manu-
facturer’s protocol. 239T and U373.MG were transfected
using the standard calcium phosphate precipitation
method. SH-SY5Y and primary mouse astrocytes were
transfected using Lipofectamine 2000 (Invitrogen, Carls-
bad, CA). For miRNA transfection, cells were plated and
cultured in a 24-well plate and transfected with miR-132
mimic (5 nM/well) and miR-132 inhibitor (50 nM/well)
using Lipofectamine 2000 (Invitrogen).
Reverse transcription quantitative polymerase chain
reaction (qRT-PCR)
RNA was isolated from cells or exosomal pellets using a
mirVana miRNA Isolation Kit (Ambion, Austin, TX) ac-
cording to the manufacturer’s protocol. A total of 1 μg
RNA was used for reverse transcription using a TaqMan
MicroRNA Reverse Transcription Kit (Applied Biosys-
tems, Foster City, CA, USA) followed by qPCR using
AmpliTaq Gold PCR Master Mix (Applied Biosystems,
Foster City, CA, USA). miR-132 levels were normalized
to snRNA U6 (cells), or let-7b (exosomes) [72], calcu-
lated as fold change based on the 2-ddCT method, and
expressed in log10 values. Real-time PCR primers were
as follows: for BDNF: 5′-CCT GGT GGA ACT TCT
TTG CGG-3′ and 5′-GAA AGC GAG CCC CAG TTT
GG-3′; for MecP2: 5′-GGA GCC TGA CCC TTC TGA
TG-3′ and 5′-GGA TGT TAG GGC TCA GGG AAG-
3′; for CCL2: 5′-CTT CTT TGG GAC ACT TGC
TGC-3′ and 5′-CTC AGC CAG ATG CAA TCA ATG-
3′; for IL-6: 5′-ACA AAC AAA TTC GGT AGA TCC
TCG-3′ and 5′-AGC CAT CTT TGG AAG GTT CAG
G-3′; and for TNF-α: 5′-TCT TCT CGA ACC CCG
AGT GA-3′ and 5′-CCT CTG ATG GCA CCA CCA
G-3′. All real-time PCR assays were run on a Bio-Rad
CFX system (Bio-Rad, Hercules, CA). All those mRNA
were normalized to β-actin unless stated otherwise.
Western blotting
Cells were washed twice with ice-cold phosphate-
buffered saline (PBS) and lysed in RIPA buffer (50 mM
Tris.HCl, pH 7.4, 150 mM NaCl, 1 % Triton X-100, 1 %
sodium deoxycholate, 0.1 % sodium dodecyl sulfate
(SDS), 2 mM PMSF, and 1× protease inhibitor cocktail
(Roche, Indianapolis, IN)) on ice for 20 min for whole
cell lysate preparation. Protein concentration was deter-
mined using a Bio-Rad DC protein assay kit (Bio-Rad,
Hercules, CA), and the optical density at 650 nm was
taken using a Bio-Rad iMark microplate reader (Bio-Rad).
Cell lysates were electrophoretically separated by 8–12 %
sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gels
and Western blot analysis with the following primary anti-
bodies: α-CREB, α-PCREB, α-BDNF (for the mature form
of BDNF), α-p250GAP, α-MecP2, α-synaptophysin, α-
PSD-95, α-C-MYC, α-CBP (Santa Cruz Biotechnology,
Dallas, TX), α-β-actin (Sigma, St. Louis, MO), α-MAP-2
(EMD Millipore, Billerica, MA), α-His (Applied Biological
Materials ABM, Richmond, BC), and α-p24 (NIH AIDS
Reagents Program, donated by Dr. Bruce Chesebro of
NIAID) [73]. Sheep anti-mouse IgG-HRP and donkey
anti-rabbit IgG-HRP from GE Healthcare (Marlborough,
MA) were used as secondary antibodies, followed by ECL
detection and imaging using a Bio-Rad ChemiDoc im-
aging system (Bio-Rad).
Immunofluorescence staining
Cells were plated and cultured in a 24-well plate con-
taining poly-lysine-coated coverslips (Sigma). Following
transfections and culturing at 37 °C for 48 h, the cells
were washed with ice-cold PBS at room temperature for
10 min, fixed in 4 % paraformaldehyde for 30 min,
permeabilized in 0.5 % Triton X-100 in PBS for 30 min,
blocked in PBS-BB (5 % BSA, 1 % non-fat milk, and
0.3 % Triton X-100 in PBS) for 1 h, stained with a pri-
mary antibody (rabbit monoclonal α-MAP-2 (1:1000 in
PBS-BB), goat α-SYP (1:250), or mouse α-PSD-95
(1:250)), then stained with a secondary antibody (goat
anti-mouse Alexa Fluor 555, goat anti-rabbit Alexa Fluor
488, or sheep anti-goat Alexa Fluor 350, all in 1:2000 in
PBS-BB, Invitrogen). Nuclei were counterstained with
0.1 μg/ml 4′, 6-diamidino-2-phenylindole (DAPI). Ex-
tensive washes with PBS were performed between each
step. Omission of the primary antibody in parallel stain-
ing was included as a control to ensure no non-specific
staining. Images were taken using a Zeiss Axiovert 200
microscope.
Lactate dehydrogenase (LDH) release assay
LDH release assay was performed using a Takara LDH
Cytotoxicity Detection Kit (Shiga, Japan). Briefly, cells
were plated in a 96-well plate and transfected as indi-
cated. Seventy-two hours post transfection, the plate was
centrifuged and 150-μl culture supernatant from each
well was transferred to a new 96-well plate. Substrate
reagent (100 μl) was then added to each well and
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incubated at 37 °C for 30 min. The plate was immedi-
ately placed in a reader and the absorbance at 490 nm
was taken. The culture supernatant from cells treated
with Triton X-100 was used as a high positive control
and media from untreated cells as a low negative con-
trol. The media without any cell growth were tested as
background. The high positive control was confirmed to
have 100 % cell lysis microscopically. Relative LDH re-
lease was calculated based on the absorbance of each
sample at 490 nm compared with the low and high con-
trols and subtraction of background.
Exosome isolation
Exosomes were prepared as we described previously [64,
74]. Briefly, the culture supernatants were collected 72 h
following transfections and cleared of cell debris by cen-
trifugation at 3000g for 10 min followed by filtration
through a 0.22-μm filter. Crude exosome pellets were
obtained by ultracentrifugation of cleared supernatants
at 100,000g for 70 min. The exosome pellets were re-
suspended in 500 μl PBS and were either frozen at −20 °C
or used immediately for uptake studies, RNA isolation, or
Western blotting. Exosome-free media were obtained by
ultracentrifugation of the complete media (serum with
antibiotic) at 100,000g for 16 h and used in all studies in-
volving exosomes.
Virus production and infection
293T cells were transfected with VSV-G and HIV.GFP
plasmids using the standard calcium phosphate precipi-
tation method. Culture supernatants were collected 72 h
post transfection, cleared of cell debris by low-speed
centrifugation and ultracentrifuged through a 6–18 %
OptiPrep™ density gradient to purify the HIV virus. The
virus titer was determined by the reverse transcriptase
assay. For infection of primary human astrocytes and
U373.MG (1 × 106), VSV-G-pseudotyped HIV equivalent
to 30,000 cpm were added to cells in 6-well plates con-
taining a 2-ml fresh medium and centrifuged at 600g in
room temperature for 2 h. Cells were then washed with
PBS to remove the input virus and were transferred to
T25 flasks containing 2 × 106 astrocytes in 18-ml
exosome-depleted F-12-K or DMEM. The percentage of
infected cells was determined for GFP expression by
flow cytometry.
Data analysis
All experiment data were analyzed by one-way ANOVA
unless stated otherwise. A p < 0.05 was considered to be
statistically significant and marked as “*”, a p < 0.01 was
considered to be statistically highly significant and
marked as “**”, and a p < 0.001 was considered to be sta-
tistically highly significant and marked as “***.”
Results
Tat expression and HIV infection-induced miR-132
expression in astrocytes and neurons
To determine the effects of Tat on miR-132 expression,
we first expressed Tat in human astrocytoma cells
U373.MG and U138.MG and human neuroblastoma
SH-SY5Y and determined miR-132 expression in those
cells. Tat expression significantly induced miR-132 level
in U373.MG and SH-SY5Y (Fig. 1a). To ascertain Tat-
induced miR-132 expression, we took advantage of the
doxycycline (Dox)-inducible astrocyte-specific Tat-
transgenic mice (iTat) [40, 57], in which Tat expression
level and resulting neuropathologies following doxycyc-
line treatment are comparable to those in the brain of
HIV-infected subjects. Primary mouse astrocytes from
wild-type (WT) and iTat mice were isolated and cultured
to induce Tat expression by Dox. miR-132 was signifi-
cantly induced in Dox-treated astrocytes derived from
iTat mice but not in other astrocytes (Fig. 1b). Next, we
determined whether miR-132 was induced in astrocytes
in the context of HIV infection. U373.MG were infected
with VSV-G-pseudotyped HIV. Compared to the mock
infection control (HIV containing no envelope), miR-132
was significantly induced in cells infected with VSV-G-
pseudotyped HIV (Fig. 1c). Similar results were obtained
in primary human astrocytes (PHA) infected with VSV-
G-pseudotyped HIV-1. Tat expression was confirmed by
Western blotting (Fig. 1a) or semi-quantitative RT-PCR
(Fig. 1b), while HIV infection was confirmed by Western
blotting for p24 (Fig. 1c). These results show that miR-
132 was significantly induced in Tat-expressing astro-
cytes and neurons and HIV-infected astrocytes.
Tat expression down-modulated expression of miR-132
target genes
As mentioned above, the mRNA targets of miR-132
within the CNS include MecP2 and p250GAP. BDNF
transcription is directly controlled by MecP2, and there-
fore, BDNF is an indirect target of miR-132. Thus, we
determined whether Tat expression altered expression of
those miR-132 target genes MecP2, p250GAP, and
BDNF. PHA were first used. miR-132 mimic (miR-
132m) was included as a control. Both Tat and miR-132
expression led to a lower level of MecP2 and BDNF pro-
tein expression in PHA (Fig. 2a). To further determine
whether Tat-induced down-modulation of MecP2 and
BDNF was mediated through miR-132, we included
miR-132 inhibitor (miR-132i) in the experiments. miR-
132i expression alone did not significantly affect consti-
tutive MecP2 and BDNF expression but considerably ab-
rogated the down-modulation of MecP2 and BDNF
expression by Tat. In addition, MecP2 and BDNF mRNA
levels were determined. There were no changes of
MecP2 mRNA by Tat, miR-132m, and/or miR-132i
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Fig. 2 Effects of Tat expression on miR-132 targets in astrocytes. a–c Primary human astrocytes were transfected with Tat.Myc, miR-132 mimic
(miR-132m), and/or miR-132 inhibitor (miR-132i), cultured for 48 h and harvested for cell lysates, followed by Western blotting (a), or RNA isolation,
followed by qRT-PCR for MecP2 (b) and BDNF (c). d–f Primary astrocytes were isolated from WT and iTat mice, cultured in the presence (+) or
absence (−) of 5 mg/ml Dox for 48 h, transfected with miR-132i, cultured for additional 24 h, and harvested for cell lysates, followed by Western
blotting (d), or RNA isolation, followed by qRT-PCR for MecP2 (e) and BDNF (f). A control miRNA and pcDNA3 were included to equalize the input
DNA or miRNA. The qPCR data were mean ± SD of triplicates and representative of three independent experiments. Western blots were quantitated
using ImageJ software. The relative protein level was calculated using β-actin as the reference, and the first control sample was set at 1.0. The data
were representative of three independent experiments
Fig. 1 miR-132 induction following Tat expression and HIV-1 infection. a U373.MG, SH-SY5Y, and U138.MG were transfected with Tat.Myc plasmid
(Tat) or the cloning vehicle pcDNA3 (C3) and cultured for 48 h and harvested for RNA extraction, followed by qRT-PCR for miR-132 level (upper panels),
or cell lysates, followed by Western blotting for Tat expression using an anti-C-MYC antibody (lower panels). β-actin was included as a loading control
for Western blotting. b Primary astrocytes were isolated from wild-type (WT) mice and doxycycline (Dox)-inducible and astrocyte-specific HIV Tat-transgenic
mice (iTat), cultured in the presence of 5 mg/ml Dox (+) or in the absence of Dox (−) for 48 h and harvested for RNA isolation, followed by qRT-PCR
for miR-132 level (upper panel) or semi-quantitative RT-PCR for Tat (lower panel). GAPDH was included as a loading control for Tat RT-PCR. c U373.MG
and primary human astrocytes (PHA) were infected with VSV-G-pseudotyped HIV (+), cultured for 3 days and harvested for RNA extraction, followed by
qRT-PCR for miR-132 level or cell lysates, followed by Western blotting for p24 expression using an anti-p24 antibody. Pseudotyped HIV containing no
envelope (−) was included as an infection control (mock). snRNA U6 level was also determined by qRT-PCR. miR-132 level was normalized to snRNA
U6 level and expressed as fold changes compared to the control. The data were mean ± SD of triplicates and/or representative of three independent
experiments. The data were analyzed using one-tailed Student’s t test, and the comparisons were made between the C3 control and Tat
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(Fig. 2b), while BDNF mRNA exhibited a pattern of
changes similar to its protein (Fig. 2c). Then, we deter-
mined the relationship between Tat expression and miR-
132 target gene expression in primary mouse astrocytes
from WT or iTat mice. Compared to WT primary astro-
cytes, Dox treatment of iTat primary astrocytes led to a
lower level of MecP2 and BDNF protein expression
(Fig. 2d), little changes in MecP2 mRNA (Fig. 2e), and a
low level of BDNF mRNA (Fig. 2f ). In parallel, miR-132i
expression significantly restored MecP2 and BDNF pro-
tein expression and BDNF mRNA expression but had
little effects on MeCp2 mRNA expression.
We also assessed the protein levels of miR-132 targets
in relation to Tat, miR-132m, and miR-132i expression
in SH-SY5Y. In addition to MecP2 and BDNF, the pro-
tein level of p250GAP, a neuron-specific target of miR-
132, was analyzed. Similar to the findings in astrocytes,
there were considerably lower levels of MecP2 and
BDNF protein and slightly lower levels of p250GAP pro-
tein in Tat- and miR-132m-transfected cells (Fig. 3).
miR-132i rescued MecP2 protein expression from Tat-
induced down-modulation but had no apparent effects
on BDNF and p250GAP expression. Taken together,
these results indicate that Tat expression resulted in
down-modulation of miR-132 target genes through miR-
132 induction.
Involvement of CREB phosphorylation and Tat basic
domain in Tat-induced miR-132 expression
HIV-1 Tat has been shown to regulate transcription of
host genes and miRNA through a number of transcrip-
tional factors including CREB [65, 75–82]. miRNA
expression is mainly regulated at the level of transcrip-
tion (see review [83]). The primary sequence, the seed
region, and the gene structure of miR-132 are well con-
served between humans and mice [27]. A total of five
transcriptional binding sites have been characterized
within the miR-132 promoter [84–86]: four sites for
CREB and one site for repressor element 1 silencing
transcription factor/neuron-restrictive factor. Thus, we
determined the possibility of the involvement of CREB
phosphorylation in Tat-induced miR-132 expression.
U373.MG were first used. Tat expression led to phos-
phorylation of CREB (Fig. 4a) and miR-132 induction
(Fig. 4b). Deletion of Tat basic domain (ΔBD) completely
abrogated Tat-induced CREB phosphorylation and miR-
132 expression. To determine the minimal level of Tat
for CREB phosphorylation, PHA were directly exposed
to different concentrations of recombinant Tat protein,
and CREB phosphorylation was determined using
Western blotting. Phosphorylated CREB was detected at
5 ng/ml recombinant Tat protein and increased with
increasing concentrations of recombinant Tat protein
Fig. 3 Effects of Tat expression on miR-132 targets in neurons.
SH-SY5Y were transfected with Tat.Myc, miR-132 mimic (miR-132m),
and/or miR-132 inhibitor (miR-132i), cultured for 48 h and harvested
for cell lysates, followed by Western blotting. A control miRNA and
pcDNA3 were included to equalize the input DNA or miRNA.
Western blots were quantitated using ImageJ software. The relative
protein level was calculated using β-actin as the reference, and the
first control sample was set at 1.0. The data were representative of
three independent experiments
Fig. 4 CREB phosphorylation by Tat and its requirement for Tat
basic domain. a, b U373.MG were transfected with Tat.His or basic
domain-deleted Tat (ΔBD.His) plasmid, cultured for 48 h and harvested
for cell lysates, followed by Western blotting (a), or RNA isolation,
followed by qRT-PCR for miR-132 level (b). C3 was used as the control,
and snRNA U6 was used to normalize miR-132 level. A control miRNA
was included to equalize the input miRNA. The qPCR data were
mean ± SD of triplicates and representative of three independent
experiments. c Primary human astrocytes were treated with recombinant
Tat protein at 0, 5, 10, 100, and 200 ng/ml for 24 h. Cell lysates were
then prepared for Western Blotting for CREB and pCREB. β-actin was
included as a loading control for Western blotting. Western blots were
quantitated using ImageJ software. The relative protein level was
calculated using β-actin as the reference, and the first control sample
was set at 1.0. The data were representative of three
independent experiments
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(Fig. 4c). The minimal level of Tat required for CREB
phosphorylation in astrocytes is close to that (up to
16 ng/ml) reported in the CSF of HIV patients [87].
Then, to determine the role of CREB phosphorylation
in Tat-induced miR-132 expression, PHA and SH-SY5Y
were transfected with Tat, along with miR-132m or miR-
132i. In PHA, Tat expression induced CREB phosphor-
ylation (Fig. 5a). Although miR-132m and miR-132i
expression did not lead to significant changes in con-
stitutive CREB phosphorylation, co-expression of Tat
and miR-132i resulted in a much higher level of CREB
phosphorylation. In SH-SY5Y, Tat expression induced
CREB phosphorylation (Fig. 5b) although both miR-
132m and miR-132i showed no effects on the constitutive
level of CREB phosphorylation. Furthermore, primary as-
trocytes from WT and iTat mice were also used to assess
the relationship between Tat expression and CREB phos-
phorylation. Compared to the WTastrocytes (Fig. 5c), iTat
astrocytes treated with Dox led to CREB phosphorylation
(Fig. 5d), which was not affected by miR-132i expression.
These results together suggest that CREB phosphorylation
and Tat basic domain are likely involved in Tat-induced
miR-132 expression.
miR-132 induction did not contribute to Tat-induced
astrocyte activation
Tat expression in astrocytes induces a highly inflamma-
tory profile and leads to the dysregulation of astrocyte
functions, termed astrocyte activation, or astrocytosis
[65, 88], characterized by increased GFAP expression
[88] and expression of pro-inflammatory cytokines such
as IL-6 and TNF-α and chemokines such as CCL2
[89–91]. Next, we determined whether miR-132 induc-
tion was involved in Tat-induced GFAP, CCL-2, IL-6,
and TNF-α expression. As shown previously [57], Tat
expression induced GFAP expression in PHA when
compared to the C3 control (Fig. 6a, b). ΔBD Tat mutant
also induced GFAP expression albeit to a lesser extent,
and miR-132i did not show any effect on GFAP expres-
sion induced by Tat or ΔBD. Tat and ΔBD expression
was confirmed by Western blotting (Fig. 6c). Similarly,
Tat induced CCL-2, IL-6, and TNF-α expression when
compared to the C3 control (Fig. 6d). But miR-132i had
little effects on constitutive and Tat-induced expression
of those molecules. In addition, we also determined ef-
fects of Tat on the LDH release, an indicator of cell via-
bility. Compared to the C3 control, Tat or ΔBD
expression showed little effects on the LDH release
(Fig. 6e). Taken together, these results suggest that miR-
132 induction is unlikely involved in Tat-induced astro-
cyte activation and that Tat expression itself does not
affect astrocyte survival.
Tat-induced miR-132 expression contributed to Tat direct
neurotoxicity
To determine whether Tat-induced miR-132 contributed
to Tat direct neurotoxicity, SH-SY5Y were transfected
with Tat and miR-132i and assayed for the LDH release
from those cells. Compared to the C3 control, Tat ex-
pression increased the LDH release from those cells
(Fig. 7). Meanwhile, miR-132i expression significantly di-
minished Tat-induced LDH release from those cells.
These results confirm that Tat has direct neurotoxic ac-
tivity and suggest that miR-132 induction could contrib-
ute to Tat neurotoxicity.
Tat expression led to increased miR-132 level in
astrocyte-derived exosomes
Virtually all eukaryotic cells including astrocytes produce
exosomes, which serve as a major extracellular vehicle
Fig. 5 CREB phosphorylation and miR132 expression. a, b Primary
human astrocytes (a) and SH-SY5Y (b) were transfected with Tat,
miR-132m, and/or miR-132i, cultured for 48 h and harvested for cell
lysates, followed by Western blotting. A control miRNA and pcDNA3
were included to equalize the input DNA or miRNA. c, d Primary
astrocytes were isolated from WT and iTat mice, cultured in the
presence (+) or absence (−) of 5 mg/ml Dox for 48 h, transfected
with miR-132i, cultured for additional 24 h, and harvested for cell
lysates, followed by Western blotting. A control miRNA was included
to equalize the input miRNA. Western blots were quantitated using
ImageJ software. The relative protein level was calculated using
β-actin as the reference, and the first control sample was set at 1.0.
The data were representative of three independent experiments
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to transport miRNA and proteins among cells [13, 72].
Thus, we first determined whether Tat-induced miR-132
expression would lead to increased miR-132 in
astrocyte-derived exosomes. Compared to the C3 con-
trol, increased miR-132 was detected in exosomes de-
rived from Tat-expressing cells (Fig. 8a). miR-132i
expression significantly decreased Tat-induced miR-132
packaging into the exosomes from astrocytes, further
supporting the notion that miR-132 is sorted into the
exosomes. The exosome purity was confirmed by lack of
cytochrome C and presence of TSG-101 in the exosomes
using Western blotting (Fig. 8b). Consistent with our
previous studies [64], Tat was also detected in the exo-
somes. To determine whether miR-132 in the form of
exosomes could be transferred from astrocytes to neu-
rons, we labeled miR-132m with Cy3 and transfected it
into U373.MG and further confirmed Cy3-labled miR-
132m transfection by flow cytometry (Fig. 8c). Further-
more, we obtained exosomes from Cy3-labled miR-
132m-transfected astrocytes and exposed them to SH-
SY5Y and determined whether those cells would take up
the labeled miRNA by flow cytometry. Cy3-labled miR-
132m were detected in those cells (Fig. 8d). These re-
sults show that Tat-induced miR-132 is packaged into
astrocyte-derived exosomes, which can be taken up by
neurons.
Astrocyte-derived miR-132 shortened neurites
We next sought to determine whether transfer of
exosome-associated miR-132 from astrocytes to neurons
would affect the morphology of neuron dendrites and
formation of synapse. To this end, WT and iTat primary
astrocytes were prepared, cultured in the presence or ab-
sence of Dox, and transfected with miR-132i, and exo-
somes were prepared from those samples and exposed
to primary mouse cortical neurons. The primary cortical
neurons were stained for MAP-2, and the neurite length
of the primary cortical neurons that were exposed to
exosomes from WT astrocytes (Fig. 9a) and exosomes
Fig. 6 Effects of miR-132 induction on GFAP expression, cytokine/chemokine expression, and astrocyte survival. Primary human astrocytes were
transfected with Tat.His (Tat), ΔBDTat.His (ΔBD), and miR-132i (miR-132i), cultured for 48 h and harvested for immunofluorescence staining for
GFAP (red) and DAPI staining for nucleus (blue) (a), Western blotting (c), or qRT-PCR (d). The mean fluorescence intensity (MFI) of GFAP expression
was determined using ImageJ software (b). Meanwhile, the cell culture supernatants were collected and assayed for the LDH release (e). The data
(b, d, e) were mean ± SD of triplicates and representative of three independent experiments
Fig. 7 Role of miR-132 induction in Tat neurotoxicity. SH-SY5Y
were transfected with Tat.Myc (Tat), miR-132i, or both and
cultured for 48 h. The cell culture supernatants were collected and
assayed for the LDH release. C3 and a control miRNA (miR-ctrl)
were used to equalize the input amount of DNA and miRNA. The
data were mean ± SD of triplicates and representative of three
independent experiments
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from iTat astrocytes (Fig. 9b) was quantitated using the
neurite trace analysis. Compared to the WT controls,
exosomes from Dox-treated iTat astrocytes showed sig-
nificantly shorter neurites (Fig. 10a), which was signifi-
cantly reversed by miR-132i expression. In parallel,
exosomes from Dox-treated iTat astrocytes increased the
LDH release from the neurons, which was significantly
diminished by miR-132i expression (Fig. 10b). Mean-
while, the exosome-treated primary cortical neurons
were also stained for synaptophysin (SYP), a pre-
synaptic marker, or postsynaptic density protein (PSD-
95), a postsynaptic marker. The density of SYP and
PSD-95 of the primary cortical neurons that were ex-
posed to exosomes from WT astrocytes (Fig. 11a) and
exosomes from iTat astrocytes (Fig. 11b) was similarly
quantitated. Compared to the WT controls, exosomes
from Dox-treated iTat astrocytes significantly decreased
the density of both SYP and PSD-95 in those cells
(Fig. 12a), which was not rescued by miR-132i expres-
sion. Similar results were obtained by Western blotting
(Fig. 12b). These results showed that Tat-induced miR-
132 in astrocytes adversely affected neurite outgrowth
and contributed to astrocyte-mediated Tat neurotoxicity.
Discussion
HIV-1 Tat damages the dendritic arbor, shortens neur-
ites, and reduces synaptic protein levels [59, 60, 63].
Widespread expression and secretion of this protein in
the CNS of the HIV-infected population despite HAART
[51] is strongly correlated with synaptodendritic damage,
the hallmark of pathology in HAND [9, 92]. The revers-
ible nature [93] of Tat’s deleterious effects on dendritic
integrity warrants a better understanding of the potential
molecular events that connect Tat to the regulation of
synaptodendritic plasticity. In this study, we first deter-
mined the potential of Tat in the induction of miR-132,
a brain-enriched microRNA with substantial roles in the
regulation of synaptodendritic plasticity. We found that
Tat significantly induces this miRNA in astrocytes and
neurons (Fig. 1), leading to the repression of the known
targets of this miRNA (Figs. 2 and 3), and causing
neurotoxicity (Fig. 7). We showed the CREB-responsive
Fig. 8 Exosomal miR-132 and its transfer to neurons. a, b U373.MG were transfected with Tat, miR-132i, or both and cultured for 48 h. The cell
culture supernatants were collected and used to isolate exosomes. RNA was isolated from exosomes and analyzed for qRT-PCR for miRNA-132
level (a). Exosomal miR-132 was normalized to let-7b. Lysates were prepared from the cells (WCL) and exosomes (EXO) and analyzed by Western
blotting (b). c, d U373.MG were transfected with Cy3 dye miR-132m (Cy3-miR-132m) or unlabeled miR-132m as a control, cultured for 12 h, and
harvested for Cy3 signal using flow cytometry (c). The cell culture supernatants were collected and used to isolate exosomes. SH-SY5Y were
cultured in the presence of the exosomes for 6 h and assayed for Cy3 signal using flow cytometry (d). The qRT-PCR data were mean ± SD of
triplicates and representative of three independent experiments. The Western blots and the flow cytometry histograms were representative of
three independent experiments
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miR-132 expression through the phosphorylation of
CREB by Tat (Fig. 5). We ruled out the possibility of
miR-132 involvement in Tat activation of astrocytes
(Fig. 6). Considering the significance of exosomal glia-
neuron communications [94] and the direct link be-
tween the miRNA processing pathway and exosomal
biogenesis [95], we determined the miR-132 content of
Tat-expressing astrocyte exosomes. We found significant
levels of miR-132 in exosomes from these astrocytes
which were taken up by neurons (Fig. 8) and resulted in
neurite shortening (Fig. 9 and 10) but were not directly
involved in reduction of synaptic protein levels by Tat
(Figs. 11 and 12). These data provide new mechanistic
insights of Tat’s injury to dendritic arbor and identify
novel pathways that potentially contribute to Tat
neurotoxicity.
We showed that HIV-1 Tat protein significantly up-
regulated miR-132 in astrocytes and neurons (Fig. 1).
Unlike an early report [96], our data did not show a dif-
ference in the basal expression levels of this microRNA
between the two cell types. Following Tat expression,
however, astrocytes showed significantly higher fold
Fig. 10 Changes of neurite lengths and neuron survival by Tat and exosomal miR-132. The average length of neurites in Fig. 9a, b above was
determined using ImageJ Neurite Tracer and calculated based on the occupied pixel areas and three randomly selected images of each treatment
group (a). The cell culture supernatants from Fig. 9a, b above were collected and assayed for LDH release (b). The data were representative of
three independent experiments
Fig. 9 Effects of Tat expression and exosomal miR-132 induction on neurite outgrowth. Primary mouse astrocytes were isolated from WT (a) and
iTat (b), cultured in the presence (+Dox) or absence of (−Dox) of 5 mg/ml for 48 h, transfected with miR-132i (+miR-132i) or a control miRNA
(−miR-132i) and continued to culture for 48 h. The cell culture supernatants were collected and used to isolate exosomes. Primary mouse cortical
neurons were plated and cultured on poly-lysine-coated coverslips in a 24-well plate at the density of 85,000 cells/well and continued to culture
in the presence of the exosomes isolated above for 48 h. Then, the cells were harvested for immunofluorescence staining for MAP-2 and counterstained
with DAPI (a, b). The images were representative of three independent experiments
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changes in miR-132 compared to neurons. This might in
part be due to the well-documented activity-dependent
nature of miR-132 expression in neurons which happens
rapidly and in a transient fashion [97]. On the other
hand, Tat transfection of neuronal cells was less efficient
compared with astrocytes as supported by our Western
blotting results which showed a lower level of Tat ex-
pression in neurons. We then demonstrated that miR-
132 induction was likely due to the ability of Tat to in-
duce phosphorylation of CREB (Fig. 5) and subsequent
binding of phosphorylated CREB to CREB-responsive el-
ements within the transcriptional control locus of miR-
132 [84]. CREB phosphorylation also promotes the bind-
ing of phosphorylated CREB to CBP, which leads to the
transactivation of the miR-132 loci containing CREB-
responsive elements [98]. Tat expression leads to
Fig. 11 Effects of Tat expression and exosomal miR-132 induction on synaptic formation. Primary mouse astrocytes were isolated from WT (a)
and iTat (b), cultured in the presence (+Dox) or absence of (−Dox) of 5 mg/ml for 48 h, transfected with miR-132i (+miR-132i) or a control miRNA
(−miR-132i) and continued to culture for 48 h. The cell culture supernatants were collected and used to isolate exosomes. Primary mouse cortical
neurons were plated and cultured on poly-lysine-coated coverslips in a 24-well plate at the density of 85,000 cells/well and continued to culture
in the presence of the exosomes isolated above for 48 h. The cells were then harvested for immunofluorescence staining for synaptophysin (SYP)
for presynapse formation and for PSD-95 for postsynapse formation and counterstained with DAPI (a, b). The images were representative of three
independent experiments
Fig. 12 Changes of SYP and PSD-95 expression by Tat and exosomal miR-132. SYP and PSD-95 immunostaining along with skeleton conversion
of fluorescent images in Fig. 11a, b above was performed, the density of synaptic protein staining was determined using ImageJ software and
based on the occupied pixel areas and three randomly selected images of each treatment group (a). The cells from Fig. 11a, b above were
harvested for cell lysates, followed by Western blotting (b). Western blots were quantitated using ImageJ software. The relative protein level was
calculated using β-actin as the reference, and the first control sample was set at 1.0. The data were representative of three
independent experiments
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phosphorylation of CREB at Ser133 through several path-
ways [78, 99, 100]. Alternatively, Tat directly binds CBP,
recruiting the histone acetyltransferase to the CRE [82].
Both CREB phosphorylation and CBP-binding activities
of Tat have been shown to be dependent on the basic
domain of this protein [101, 102]. Our data showed
complete abrogation of CREB phosphorylation and lack
of miR-132 induction following transfection with basic
domain-deleted Tat (Fig. 4a, b), further supporting Tat
effects on CREB phosphorylation and the requirement
of Tat basic domain for this effect. Despite a comparable
level of Tat-induced CREB phosphorylation in both as-
trocytes (Fig. 5a) and neurons (Fig. 5b), the basal levels
of total CREB and phosphorylated CREB in neurons
were higher than those in astrocytes. This difference is
likely due to the fact that there are more constitutive
CREB activation pathways in neurons than astrocytes
such as calcium signaling-associated and B-raf kinase-
mediated MAPK-dependent phosphorylation of CREB
[103–105].
miR-132 plays a crucial role in the development of
neurons by regulating two targets in charge of control-
ling neurite outgrowth: MecP2, which is a potentiating
factor of neurite growth, and p250GAP, which inhibits
the outgrowth of neurites [27, 106]. The question is then
which direction miR-132 expression takes the neurons
in regard to neurite growth while this microRNA
represses both an enhancer and an inhibitor of neurite
outgrowth. The different temporal expression of
p250GAP and MecP2 in development may likely provide
the key. p250GAP is involved in neuronal differentiation
and is expressed prior to MecP2 [107]. In fact, the stud-
ies that discovered p250GAP as a target of miR-132 only
found repression of this target in immature neurons [84]
and showed that miR-132 overexpression led to the en-
hancement of neurite outgrowth due to the repression
of p250GAP. Studies performed on adult neurons, how-
ever, showed the complete opposite; overexpressing
miR-132 in adult neurons leads to a significant decrease
in dendritic growth [108], which is due to MecP2 repres-
sion. MecP2 is expressed starting at the 10th gestational
week and is required for the maintenance of adult neurons
[109]. Our data are in agreement with these findings indi-
cating the repression of MecP2 in fully differentiated neur-
onal cells while p250GAP levels are unchanged (Fig. 3).
p250GAP expression in adult neurons has been found to
be activity dependent and controlled by NMDA receptor
signaling events [107].
MecP2 has significant roles in neurogenesis, neuronal
differentiation, and proper development of dendritic
arbor [110, 111]. This major target of miR-132 in the
CNS has been found to be dysregulated in HAND [112].
BDNF, another important regulator of dendritic growth
[113, 114] and synaptic function [115, 116] which shows
notable reduction in the brain and serum of HIV-
infected subjects [117, 118], is directly and positively
regulated by MecP2 [119]. In fact, an axis of regulation
exists in the brain involving BDNF, miR-132, and MecP2
[29], in which BDNF induces miR-132 through phos-
phorylation of CREB [120, 121]. As a target of miR-132,
MecP2 is ultimately repressed, leading to the repression
of BDNF due to the negative regulatory feedback nature
of this axis. Improper timing or duration of miR-132 ex-
pression has been shown to be neurotoxic, indicating
the delicate balance in the regulation of this axis [122].
Rett syndrome, an autism spectrum disorder resulting
from genetic mutation in the MecP2 gene [123], shares
striking similarities in neuropathology with HAND.
MecP2 is essential for the proper outgrowth of dendrites
and formation of synapses [111]. The activity-dependent
expression of this protein starts prior to synaptogenesis
in development and is tightly controlled in most adult
neurons [124]. Reduced size and branching of dendrites
inflicted by the lack of MecP2 expression in the develop-
ing brain result in microcephaly and mental retardation.
Interestingly, RNA levels of MecP2 do not differ in fetal
and adult brains while its expression is not similar in dif-
ferent neuronal populations [125]. This is indicative of
posttranscriptional control of MecP2 by miRNA and is
in agreement with our data that failed to find changes in
MecP2 mRNA but showed significant reduction in
MecP2 protein and consequently BDNF, the transcrip-
tion of which depends on MecP2 (Figs. 2 and 3).
To discern the direct detrimental effects of Tat on
neurons from miR-132 overexpression, we employed
synthetic miR-132 inhibitor in our experiments. We
confirmed that miR-132 inhibitor transfection efficiently
antagonized miR-132 (data not shown). Next, we showed
that miR-132 overexpression was at least in part respon-
sible for Tat neurotoxicity (Fig. 7). Antagonizing miR-
132 expression also led to reduced exosomal levels of
miR-132 (Fig. 8a). In our previous study, we reported
exosome-associated Tat release from Tat-expressing and
HIV-1 infected cells [64]. With miR-132 inhibitor ex-
pression, we were able to conclude that overexpression
of miR-132 was responsible for neurite shortening in
neurons treated with exosomes from Tat-expressing as-
trocytes (Fig. 10a), as antagonizing miR-132 improved
neurite lengths even in presence of Tat-containing exo-
somes. Similarly, we also showed that exosomal miR-132
contributes to neurotoxicity (Fig. 9b). Although miR-132
inhibitor expression consistently negated the Tat-
induced down-modulation of MecP2 in astrocytes
(Fig. 2a, d) and neurons (Fig. 3), its effects on rescuing
BDNF levels were not consistent across cell types. Only
astrocytes (Fig. 2a, d) showed improved BDNF levels
with miR-132i transfection, while neurons (Fig. 3) did
not show such an effect. This might be due to the
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temporal difference that exists in MecP2-induced BDNF
expression. Antagonizing miR-132 in presence of Tat
rescues MecP2 levels as the direct target of miR-132.
This process rapidly improves BDNF mRNA levels
(Fig. 2c, f ), while this improvement is not reflected in
protein levels of BDNF as rapidly.
miR-132 has been shown to increase the width of den-
dritic spines, which are storage sites for post synaptic
density, contain glutamate receptors, and increase the
contact points between neurons [108]. These protrusions
also establish contact with synaptic terminals containing
synaptophysin [126]. Therefore, it has been suggested
that miR-132 may affect the strength of excitatory
synapses [127]. Our analysis of synaptic protein levels in
cortical neurons treated with exosomes derived from
Tat-expressing astrocytes (+DOX −miR-132i/+DOX +
miR-132i) reduced both SYP and PSD-95. Moreover, re-
ducing miR-132 levels in exosomes did not change the
significant loss of these proteins (Figs. 11a, b and 12a).
Western blotting data from these neurons also showed
consistent reduction in both SYP and PSD-95, and al-
though there was no change in PSD-95 with miR-132i,
SYP levels showed improvement with reduced exosomal
miR-132 (Fig. 12b). However, lack of consistency be-
tween the effects of miR-132 inhibition on the two pro-
teins and reduction in protein levels of neurons treated
with WT exosomes prevent us from concluding that
miR-132 affected synaptic protein levels or synapse for-
mation. MAP-2 protein levels were consistent with the
miR-132-dependent reduction in neurite lengths by Tat
and increase in neurite lengths by miR-132 inhibition
despite of Tat expression. These results are in agreement
with Tat’s direct involvement in the reduction of post-
synaptic proteins followed by negative feedback [59, 61]
on pre-synaptic proteins.
In summary, the findings from the current study sup-
port a new model of Tat-impaired neurite outgrowth
and neuron survival (Fig. 13). Tat-impaired neurite out-
growth could be direct and astrocyte mediated. Tat up-
take into neurons induces miR-132 expression through
CREB phosphorylation, down-regulates MecP2 and
BDNF expression in neurons, and impairs neurite out-
growth and neuron survival; alternatively, Tat expression
in astrocytes resulting from HIV-1 infection or Tat up-
take into astrocytes induces miR-132 expression through
CREB phosphorylation and down-regulates BDNF ex-
pression. miR-132 induction in astrocytes leads to in-
creased miR-132 release into exosomes from astrocytes,
uptake of exosome-associated miR-132 into neurons,
and down-regulation of MecP2 and BDNF expression in
neurons and impairs neurite outgrowth and neuron sur-
vival. In addition, BDNF down-regulation in astrocytes
results in less BDNF available for neurons and adversely
affects neurite outgrowth and neuron survival.
Conclusions
In this study, we report for the first time the induction
of miR-132 by Tat and its contribution to Tat-induced
neurite shortening and neurotoxicity. The results show
that Tat induces miR-132 by activating CREB, the tran-
scriptional control locus of miR-132. We also show that
Tat-induced miR-132 leads to the repression of MecP2
and BDNF, known targets of miR-132 in the brain. Cor-
respondingly, the miR-132 level in exosomes from Tat-
expressing astrocytes shows significant increase and
leads to neurite shortening and neurotoxicity following
uptake in neurons.
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